EQS-News: BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Retrieved on:
Sunday, December 18, 2022
Breast cancer, Immunotherapy, Woman, MBC, Quality of life, Mortality, Breast, NYSE, Mayo Clinic, Advertising, Progression-free survival, Food, FDA, Poster, Safety, Cancer, Hologic, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biotechnology, BCT, Female, Recurrence, Pfizer, Toxicity, Survival, TSX, Research, Disease, HOLX, Patient, PFE, Pharmaceutical industry, Birth control, Medical imaging
As it stands now, breast cancer is the second most common cause of cancer death in women in the U.S.
Key Points:
- As it stands now, breast cancer is the second most common cause of cancer death in women in the U.S.
- An estimated 684,996 women worldwide died from breast cancer in 2020, with metastatic breast cancer causing the vast majority of the deaths.
- Positive clinical data reported includes tumor shrinkage, disease control, progression-free survival, and potential long-term survival benefit in advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen.
- “Better quality of life” and “less pain” reported by many gravely ill advanced metastatic breast cancer patients treated with the Bria-IMT™ combination regimen.